Stockscreener 앱 받기
1.89
0.00%
0.00
시간 외 거래:
1.79
-0.10
-5.29%
전일 마감가:
$1.89
열려 있는:
$1.95
하루 거래량:
1.03M
Relative Volume:
1.39
시가총액:
$4.29M
수익:
-
순이익/손실:
$-22.71M
주가수익비율:
-0.1614
EPS:
-11.71
순현금흐름:
$-18.24M
1주 성능:
+8.00%
1개월 성능:
-43.75%
6개월 성능:
-85.30%
1년 성능:
-95.57%
1일 변동 폭
$1.785
$2.03
1주일 범위
$1.71
$2.03
52주 변동 폭
$1.71
$55.00
Genprex Inc Stock (GNPX) Company Profile
명칭
Genprex Inc
전화
512-537-7997
주소
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
GNPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
1.89 | 4.29M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-26 | 개시 | National Securities | Buy |
| 2019-04-29 | 개시 | Noble Capital Markets | Outperform |
Genprex Inc 주식(GNPX)의 최신 뉴스
Genprex Advances Diabetes Gene Therapy Program With Preclinical Milestones - Nasdaq
Genprex reports in vivo proof of concept for GPX-002 - BioWorld MedTech
Genprex reports positive data for diabetes gene therapy in animal studies - Investing.com Nigeria
Genprex advances GPX-002 diabetes gene therapy program - TipRanks
Genprex, Inc. Announces Updates on Diabetes Gene Therapy Program - TradingView — Track All Markets
Genprex Provides Clinical Update on Diabetes Gene Therapy Program - PR Newswire
Genprex Advances Diabetes Gene Therapy with Key Milestones Achieved in 2025 - Intellectia AI
Genprex Inc surges 9.44% amid market context - Intellectia AI
Genprex Reports Positive Preclinical Data for Diabetes Gene Therapy in Animal Studies; Shares Rise - marketscreener.com
Genprex Reports Positive Preclinical Data For Diabetes Gene Therapy Candidate GPX-002 - Nasdaq
Genprex reports positive data for diabetes gene therapy in animal studies By Investing.com - Investing.com South Africa
Genprex Reports Positive Preclinical Results for GPX-002 Diabetes Therapy - TipRanks
Genprex Announces Positive Preclinical Data for GPX-002 in Diabetes - TradingView — Track All Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Experimental gene therapy rejuvenates insulin cells in Type 2 diabetes tests - Stock Titan
MSN Money - MSN
Genprex (GNPX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Published on: 2025-12-29 06:37:03 - moha.gov.vn
Genprex reports potential compliance with Nasdaq equity listing rule By Investing.com - Investing.com Canada
Genprex (GNPX) awards 28,500 RSUs to Chief Medical Officer under 2018 plan - Stock Titan
Genprex (GNPX) CEO Ryan Confer reports 45,000 RSUs award - Stock Titan
Genprex (GNPX) grants director 9,000 RSUs after reverse stock split - Stock Titan
Genprex reports potential compliance with Nasdaq equity listing rule - Investing.com
Genprex Updates on Nasdaq Compliance Efforts - TradingView — Track All Markets
Street Watch: Will Genprex Inc stock split attract more investorsMarket Trend Review & Real-Time Stock Movement Alerts - moha.gov.vn
How Genprex Inc. stock reacts to inflationary pressuresWeekly Gains Summary & Safe Entry Momentum Stock Tips - Bölüm Sonu Canavarı
Aug Catalysts: How Genprex Inc. stock reacts to inflationary pressuresQuarterly Profit Review & Verified Chart Pattern Signals - moha.gov.vn
Can Genprex Inc. stock beat market expectations this quarterJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
What catalysts could drive Genprex Inc. stock higherJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда
How Genprex Inc. stock performs in high volatility marketsInflation Watch & Free Real-Time Market Sentiment Alerts - Улправда
Momentum Shift: Why Genprex Inc stock remains on buy listsEarnings Risk Summary & Fast Moving Stock Watchlists - moha.gov.vn
Will Genprex Inc. (2DE0) stock benefit from mergers2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Dividend Watch: Can Genprex Inc. stock beat market expectations this quarterPortfolio Update Report & Technical Confirmation Trade Alerts - Улправда
Why analysts upgrade Genprex Inc. stock2025 Buyback Activity & Fast Moving Stock Watchlists - DonanımHaber
Will Genprex Inc. stock sustain high P E ratios2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - DonanımHaber
How Genprex Inc. (2DE0) stock reacts to new regulationsQuarterly Portfolio Report & AI Based Trade Execution Alerts - Улправда
Why Genprex Inc. stock is rated strong buyJuly 2025 Final Week & Community Consensus Trade Signals - DonanımHaber
Is Genprex Inc. stock a smart buy before Fed meetingQuarterly Profit Report & Accurate Buy Signal Notifications - DonanımHaber
Genprex Secures U.S. Patent for Reqorsa® Therapy - MSN
Genprex Inc Stock Analysis and ForecastSector-Based Investing & High Yield Market Growth - earlytimes.in
Will Genprex Inc. (2DE0) stock recover faster than industry2025 Analyst Calls & Risk Managed Investment Signals - Newser
Is Genprex Inc. (2DE0) stock undervalued after correctionJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Is Genprex Inc. stock cheap at current valuationWeekly Profit Report & Community Driven Trade Alerts - Newser
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of - Benzinga
Can Genprex Inc. (2DE0) stock reach $200 price targetEarnings Growth Summary & Entry and Exit Point Strategies - Newser
Get in on Genprex Inc’s (GNPX) buy-in window today! - setenews.com
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Inc (GNPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):